Concepedia

279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

C. Saura Manich, Shanu Modi, Ian E. Krop, Y.H. Park, S-B. Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Junji Tsurutani, Joohyuk Sohn,

Annals of Oncology · 2021 · 32 citations · 0 references

Concepts

MedicineOncologyPharmacologyBreast OncologyImmunotherapyMetastasisBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerImmunotherapy For Breast CancerMalignant NeoplasmsMetastatic Breast CancerHer2 InhibitorsHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerPhase Ii Investigation